Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that carries several separate regulatory approvals rather than a single blanket clearance. Two distinct brand products at different doses cover type 2 diabetes on one side and chronic weight management on the other, with an added cardiovascular risk indication and pediatric extensions layered on top. Each approved condition is tied to a specific product, dose, and labeled patient population, not to the molecule in the abstract.
Liraglutide holds separate approvals for type 2 diabetes at up to 1.8 mg daily and for chronic weight management at 3.0 mg daily, plus a cardiovascular risk-reduction indication and pediatric extensions reaching ages 10 and 12.
The type 2 diabetes indication is the original authorization: an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The label positions the drug after metformin and within combination regimens rather than as first-line monotherapy, and pivotal trials recorded placebo-adjusted hemoglobin A1c reductions on the order of one percentage point alongside a low intrinsic risk of hypoglycemia when used without insulin or a sulfonylurea.
Liraglutide's founding indication is glycemic control in adults with type 2 diabetes, delivered as a once-daily subcutaneous injection titrated from a 0.6 mg starting dose to a maximum of 1.8 mg daily.
For chronic weight management, liraglutide is authorized at a higher 3.0 mg once-daily maintenance dose as an adjunct to a reduced-calorie diet and increased physical activity. Eligibility rests on body composition rather than a metabolic diagnosis, and the label frames the drug as chronic therapy for a chronic disease, with weight regain expected once treatment stops.
The weight management product is dosed to 3.0 mg once daily for adults with a BMI of 30 or greater, or 27 or greater alongside a weight-related comorbidity, and its label sets a 4 percent early-response stopping rule at 16 weeks.
Within the diabetes product line, liraglutide carries a distinct indication to reduce major adverse cardiovascular events in adults who already have established cardiovascular disease. The claim rests on a dedicated cardiovascular outcomes trial in high-risk type 2 diabetes patients, and it stays confined to the diabetes product rather than the weight product, and to secondary prevention rather than a primary-prevention population.
Liraglutide's 1.8 mg diabetes product reduces the three-point composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by roughly 13 percent in adults with type 2 diabetes and established cardiovascular disease.
The pediatric approvals arrived after the adult authorizations and are keyed to distinct age floors for each condition. Both expansions were supported by their own randomized controlled trials in the relevant age groups rather than by extrapolation from adult data, reflecting the regulatory requirement for dedicated pediatric evidence before a labeled indication is granted.
| Criteria | Diabetes | Weight management |
|---|---|---|
| Minimum age | 10 years | 12 years |
| Threshold | Type 2 diabetes diagnosis | Body weight above 60 kg, BMI at the 95th percentile or greater |
| Evidence | Dedicated pediatric trial | Dedicated pediatric trial |
Liraglutide's diabetes indication extends to children aged 10 and older, and its weight management indication to adolescents aged 12 and older who exceed 60 kg and sit at or above the 95th BMI percentile for age and sex.
The boundaries of approval carry as much weight as the indications themselves. Liraglutide has no role in type 1 diabetes or diabetic ketoacidosis because it depends on residual beta-cell function and does not replace insulin, and it carries a boxed contraindication tied to thyroid C-cell tumor signals observed in rodent studies.
Liraglutide is not approved for type 1 diabetes or diabetic ketoacidosis, carries a boxed contraindication in medullary thyroid carcinoma or MEN 2 syndrome, and is labeled against co-administration with another GLP-1 receptor agonist.
One molecule reaches patients through two separately branded and separately labeled products, and the mapping drives prescribing. The higher ceiling on the weight product reflects the dose-response curve for appetite and weight, while the diabetes product stops at the dose that balances glycemic benefit against tolerability; a fixed-dose combination with basal insulin exists as a third product carrying its own diabetes indication.
| Criteria | Diabetes product | Weight product |
|---|---|---|
| Maximum dose | 1.8 mg daily | 3.0 mg daily |
| Indications | Glycemic control, cardiovascular risk | Chronic weight management only |
| Population | Adults with type 2 diabetes | Adults with obesity or overweight plus a comorbidity |
Liraglutide reaches patients as two non-interchangeable products, a 1.8 mg diabetes product carrying the glycemic and cardiovascular indications, and a separate 3.0 mg product carrying only the chronic weight management indication.
Eligibility for the weight management indication is set by measurable thresholds rather than clinical judgment alone, which keeps the labeled population precise. A patient who falls below the thresholds sits outside the approved use even when weight loss is clinically desirable.
The weight management indication requires an initial BMI of 30 kg/m2 or greater, or 27 kg/m2 or greater with a weight-related comorbidity, while adolescents instead need body weight above 60 kg and a BMI at the 95th percentile or higher.
Liraglutide's approvals accumulated in stages rather than arriving together, which is why one molecule now spans several labeled uses. Major agencies broadly align on the core indications, though exact wording, age floors, and comorbidity language differ slightly between jurisdictions, so the precise approved condition reads from the relevant regional label rather than assumed identical everywhere.
Liraglutide's approvals were built in stages, beginning with type 2 diabetes around 2010, followed by chronic weight management at 3.0 mg, then cardiovascular risk reduction, and finally pediatric extensions to ages 10 and 12.
Educational use only. This article describes what the published scientific and clinical literature reports about Liraglutide. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
Talk to a licensed prescriber. Whether a treatment described here is appropriate for you depends on your medical history, your current medications, and the monitoring you may need. A licensed healthcare provider can evaluate your situation.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
